CISNAF

Reason for request

Clinical Benefit

Substantial

The actual benefit of this medicinal product is substantial.

Clinical Added Value

minor

CISNAF provides a level IV (minor) in improvement in actual benefit (IAB) compared to technetium scintigraphy in the detection of bone metastases in lung, prostate and breast cancers because of its superiority in diagnostic performance and in the reduction in adverse effects compared with the comparator.